Skip to content
OpenCapital
Get started

Pacific Biosciences of California PACB Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Illumina logo
IlluminaILMN
——
Revvity logo
RevvityRVTY
——
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
——
Cohu logo
CohuCOHU
——
CareDx logo
CareDxCDNA
——

Segments

By segment

See full
Reportable Segment$0+100%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's contingent consideration fair value adjustments?
Pacific Biosciences of California (PACB) reported contingent consideration fair value adjustments of $0 in Q1 2026.
How has Pacific Biosciences of California's contingent consideration fair value adjustments changed year-over-year?
Pacific Biosciences of California's contingent consideration fair value adjustments increased by 100.0% year-over-year, from -$18.7M to $0.
What is the long-term trend for Pacific Biosciences of California's contingent consideration fair value adjustments?
Over 4 years (2021 to 2025), Pacific Biosciences of California's contingent consideration fair value adjustments has grown at a 101.1% compound annual growth rate (CAGR), from $1.14M to -$18.7M.